Cargando…

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia

INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalec, Kaarina, Kingwell, Elaine, Carruthers, Robert, Marrie, Ruth Ann, Bernatsky, Sasha, Traboulsee, Anthony, Ross, Colin J D, Carleton, Bruce, Tremlett, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623385/
https://www.ncbi.nlm.nih.gov/pubmed/28576902
http://dx.doi.org/10.1136/bmjopen-2017-016276
_version_ 1783268073906634752
author Kowalec, Kaarina
Kingwell, Elaine
Carruthers, Robert
Marrie, Ruth Ann
Bernatsky, Sasha
Traboulsee, Anthony
Ross, Colin J D
Carleton, Bruce
Tremlett, Helen
author_facet Kowalec, Kaarina
Kingwell, Elaine
Carruthers, Robert
Marrie, Ruth Ann
Bernatsky, Sasha
Traboulsee, Anthony
Ross, Colin J D
Carleton, Bruce
Tremlett, Helen
author_sort Kowalec, Kaarina
collection PubMed
description INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of multiple sclerosis (MS). The use of DMF in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol for a case–control study designed to discover genomic variants associated with DMF-induced lymphopenia. The ultimate goal is to replicate these findings and create an efficient and adaptable approach towards the identification of genomic markers that could assist in mitigating adverse drug reactions in MS. METHODS AND ANALYSIS: The population sample will comprise DMF-exposed patients with MS, with cases representing those who developed lymphopenia and controls who did not. DNA genotyping will take place using a high-throughput genome-wide array. Fine mapping and imputation will be performed to focus in on the potentially causal variants associated with lymphopenia. Multivariable logistic regression will be used to compare genotype and allele frequencies between the cases and the controls, with consideration of potential confounders. The association threshold will be set at p<1.0×10(−5) for the discovery of genomic association analyses to select variants for replication. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the respective research ethics board, which includes written informed consent. Findings will be disseminated widely, including at scientific conferences, via podcasts (targeted at both healthcare professionals as well as patients and the wider community), through patient engagement and other outreach community events, written lay summaries for all participants and formal publication in peer-reviewed scientific journals.
format Online
Article
Text
id pubmed-5623385
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56233852017-10-10 Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia Kowalec, Kaarina Kingwell, Elaine Carruthers, Robert Marrie, Ruth Ann Bernatsky, Sasha Traboulsee, Anthony Ross, Colin J D Carleton, Bruce Tremlett, Helen BMJ Open Neurology INTRODUCTION: Adverse drug reactions (ADRs) are a global public health issue. The potential for pharmacogenomic biomarkers has been demonstrated in several therapeutical areas, including HIV infection and oncology. Dimethyl fumarate (DMF) is a licensed disease-modifying therapy for the treatment of multiple sclerosis (MS). The use of DMF in MS has been associated with a severe reduction in lymphocyte counts and reports of progressive multifocal leukoencephalopathy. Here, we outline the protocol for a case–control study designed to discover genomic variants associated with DMF-induced lymphopenia. The ultimate goal is to replicate these findings and create an efficient and adaptable approach towards the identification of genomic markers that could assist in mitigating adverse drug reactions in MS. METHODS AND ANALYSIS: The population sample will comprise DMF-exposed patients with MS, with cases representing those who developed lymphopenia and controls who did not. DNA genotyping will take place using a high-throughput genome-wide array. Fine mapping and imputation will be performed to focus in on the potentially causal variants associated with lymphopenia. Multivariable logistic regression will be used to compare genotype and allele frequencies between the cases and the controls, with consideration of potential confounders. The association threshold will be set at p<1.0×10(−5) for the discovery of genomic association analyses to select variants for replication. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the respective research ethics board, which includes written informed consent. Findings will be disseminated widely, including at scientific conferences, via podcasts (targeted at both healthcare professionals as well as patients and the wider community), through patient engagement and other outreach community events, written lay summaries for all participants and formal publication in peer-reviewed scientific journals. BMJ Publishing Group 2017-06-02 /pmc/articles/PMC5623385/ /pubmed/28576902 http://dx.doi.org/10.1136/bmjopen-2017-016276 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Neurology
Kowalec, Kaarina
Kingwell, Elaine
Carruthers, Robert
Marrie, Ruth Ann
Bernatsky, Sasha
Traboulsee, Anthony
Ross, Colin J D
Carleton, Bruce
Tremlett, Helen
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title_full Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title_fullStr Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title_full_unstemmed Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title_short Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
title_sort application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623385/
https://www.ncbi.nlm.nih.gov/pubmed/28576902
http://dx.doi.org/10.1136/bmjopen-2017-016276
work_keys_str_mv AT kowaleckaarina applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT kingwellelaine applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT carruthersrobert applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT marrieruthann applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT bernatskysasha applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT traboulseeanthony applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT rosscolinjd applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT carletonbruce applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia
AT tremletthelen applicationofpharmacogenomicstoinvestigateadversedrugreactionstothediseasemodifyingtreatmentsformultiplesclerosisacasecontrolstudyprotocolfordimethylfumarateinducedlymphopenia